BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Synageva BioPharma 

Corporate Offices
128 Spring Street, Suite 520
Lexington  Massachusetts  02421  U.S.A.
Phone: 781-890-1111 Fax: 781-890-1114


SEARCH JOBS

Synageva BioPharma is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. Our lead program, SBC-102, an enzyme replacement therapy for LAL Deficiency, is currently being evaluated in global Phase I/II clinical trials. SBC-102 has been granted orphan designations by the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency and fast track designation by the FDA. Synageva has several protein therapeutics focused on life threatening conditions in its pipeline. The Company has assembled a team with a proven record of bringing orphan therapies to patients.


 Key Statistics


Email: info@synageva.com
Ownership: Public

Web Site: Synageva BioPharma
Employees:
Symbol: GEVA
 









 Company News
Synageva BioPharma (GEVA) Release: LAL Deficiency Disease Review Published In Atherosclerosis 4/21/2014 9:37:22 AM    More...
Synageva BioPharma (GEVA) Announces Pricing Of Public Offering Of Common Stock 3/6/2014 8:57:57 AM    More...
Synageva BioPharma (GEVA) Announces A 2.00 Million Share Proposed Public Offering Of Its Common Stock 3/5/2014 9:41:29 AM    More...
Synageva BioPharma (GEVA) Reports 2013 Full Year Financial Results 3/4/2014 7:02:09 AM    More...
Synageva BioPharma (GEVA) Issued U.S. Patent For Treatment Of LAL Deficiency 3/4/2014 6:46:50 AM    More...
Synageva BioPharma (GEVA) Joins National Organization for Rare Disorders, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2014 2/28/2014 8:56:54 AM    More...
Synageva BioPharma (GEVA) To Present At The Cowen and Company Health Care Conference 2/21/2014 8:18:12 AM    More...
Synageva BioPharma (GEVA) To Host 2013 Fourth Quarter And Full Year Financial Results Conference Call On March 3 2/19/2014 6:49:40 AM    More...
Synageva BioPharma (GEVA) Highlights Sebelipase Alfa And LAL Deficiency Data At The Lysosomal Disease Network (LDN) WORLD Symposium™ 2/14/2014 8:57:40 AM    More...
Synageva BioPharma (GEVA) Highlights SBC-103 Data At The Lysosomal Disease Network (LDN) WORLD Symposium™ 2/13/2014 8:54:58 AM    More...
123456789

//-->